Pancreatic Adenocarcinoma Clinical Trials

53 recruiting

Pancreatic Adenocarcinoma Trials at a Glance

114 actively recruiting trials for pancreatic adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 2 with 54 trials, with the heaviest enrollment activity in New York, Houston, and Boston. Lead sponsors running pancreatic adenocarcinoma studies include Mayo Clinic, Ruijin Hospital, and Alpha Tau Medical LTD..

Browse pancreatic adenocarcinoma trials by phase

Treatments under study

About Pancreatic Adenocarcinoma Clinical Trials

Looking for clinical trials for Pancreatic Adenocarcinoma? There are currently 53 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreatic Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreatic Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 114 trials

Recruiting
Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell CarcinomaResectable Pancreatic CarcinomaResectable Pancreatic Adenocarcinoma+4 more
National Cancer Institute (NCI)152 enrolled453 locationsNCT04858334
Recruiting
Phase 1

A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer

Pancreatic Adenocarcinoma Non-resectable
Continuity Biosciences, LLC12 enrolled2 locationsNCT07481383
Recruiting
Phase 1Phase 2

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Locally Advanced Pancreatic AdenocarcinomaLocally Advanced Pancreas CancerLocally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma36 enrolled4 locationsNCT07157033
Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled17 locationsNCT07252232
Recruiting
Phase 3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled3 locationsNCT07562152
Recruiting
Phase 1

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)15 enrolled26 locationsNCT06892054
Recruiting
Phase 2

FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers

CholangiocarcinomaPancreatic Adenocarcinoma
University Hospital, Bordeaux120 enrolled1 locationNCT07478523
Recruiting
Early Phase 1

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

Metastatic Pancreatic CancerLocally Advanced Pancreatic Adenocarcinoma
University of California, Davis30 enrolled1 locationNCT04665947
Recruiting
Phase 2

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Pancreatic AdenocarcinomaPancreatic Neuroendocrine TumorGastrointestinal Neuroendocrine Tumor+4 more
University of Michigan Rogel Cancer Center66 enrolled3 locationsNCT05988918
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Pancreatic Adenocarcinoma+2 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 1Phase 2

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Metastatic Pancreatic CancerPancreatic AdenocarcinomaBasal Cell Neoplasm
UNC Lineberger Comprehensive Cancer Center104 enrolled1 locationNCT06483555
Recruiting
Phase 2

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic Adenocarcinoma
Medical University of South Carolina52 enrolled1 locationNCT07076212
Recruiting
Phase 1

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Gastric AdenocarcinomaPancreatic AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.398 enrolled45 locationsNCT05365581
Recruiting
Phase 2

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Resectable Pancreatic Adenocarcinoma+2 more
Emory University36 enrolled1 locationNCT06423326
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled158 locationsNCT04389632
Recruiting
Phase 3

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.614 enrolled13 locationsNCT07409272
Recruiting
Phase 2

A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment

Locally Advanced Pancreatic Adenocarcinoma
University Health Network, Toronto43 enrolled2 locationsNCT06453486
Recruiting
Phase 1

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Breast CancerOvarian CancerColorectal Carcinoma+4 more
AstraZeneca45 enrolled18 locationsNCT05877599
Recruiting
Phase 1Phase 2

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Pancreatic AdenocarcinomaGastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.150 enrolled8 locationsNCT07488676
Recruiting
Phase 2

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Pancreatic CancerPancreas CancerPancreatic Adenocarcinoma+1 more
Washington University School of Medicine36 enrolled1 locationNCT07126158